MediciNova, Inc. MNOV
1.41 USD +0.01 (+0.71%)
At closeNov 11, 2026, 4:00 PM EST
1.41 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
1.40 Day range 1.43
1.22 52-week range 3.90
- YTD
- +7.63%
- 1 year
- -12.42%
News
defenseworld.net CorMedix (NASDAQ:CRMD) vs. MediciNova (NASDAQ:MNOV) Financial Analysis CorMedix (NASDAQ: CRMD - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
benzinga.com MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results…
defenseworld.net MediciNova, Inc. (NASDAQ:MNOV) Stock Has Average Target Price of $7.75 MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports.…
defenseworld.net MediciNova (NASDAQ:MNOV) Stock Price Breaks Above Two Hundred Day Moving Average – Here’s Why MediciNova, Inc. (NASDAQ: MNOV - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $1.51 and…
globenewswire.com MediciNova to Participate in the Maxim Growth Summit LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange…
defenseworld.net Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head Contrast Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY)…
benzinga.com MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia…
benzinga.com MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles MediciNova reported Phase 2 topline trial results for tipelukast in treating NAFLD and hypertriglyceridemia.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY)…
benzinga.com MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant Study OverviewMN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of MN-001 in 40 patients with NAFLD and…
globenewswire.com MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat MN-001 showed…
benzinga.com MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166…
globenewswire.com MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies…
benzinga.com This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
benzinga.com Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6 Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
globenewswire.com MediciNova to Participate in Two Investor Conferences in September LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock…
zacks.com MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates MediciNova (MNOV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.07 per share a year ago.
globenewswire.com MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange…
globenewswire.com MediciNova CEO Provides Shareholder Update LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange…- benzinga.com MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 antibodies, but also a broad…
globenewswire.com MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange…
globenewswire.com MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) LA JOLLA, Calif. , May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc. , a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock…
globenewswire.com New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock…
defenseworld.net MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average – Here’s What Happened MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.43 and traded as high as $1.43.…
benzinga.com This Qualcomm Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday 
benzinga.com This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts changed outlook for top names like SUNB, SLDP, ZVRA, COHU, and MNOV. See analyst ratings page for more info. Consider buying COHU stock.- benzinga.com HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10 HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $10.
globenewswire.com MediciNova to Participate at the 38th Annual ROTH Conference LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock…
defenseworld.net MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages Shares of MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) have earned an average rating of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat reports. One…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.- benzinga.com MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Patients Have Been Enrolled In The SEANOBI Study MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the…
globenewswire.com MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange…- benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
benzinga.com MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful…- benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
benzinga.com MediciNova Completes Patient Enrollment In Its Phase 2 MN-001-NATG-202 Trial Of MN-001 (Tipelukast) For Hypertriglyceridemia And Non-alcoholic Fatty Liver Disease Due To Type 2 Diabetes, Top-Line Data Are Expected By The Summer Of 2026 The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001(tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
benzinga.com Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket 
benzinga.com Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research.- benzinga.com D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
- benzinga.com MediciNova Completes Patient Enrollment In Phase 2/3 Clinical Trial, COMBAT-ALS For Treatment Of Amyotrophic Lateral Sclerosis MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful…
- benzinga.com MediciNova Issues Shareholder Update; Secures $30M SEPA To Advance R&D As COMBAT-ALS Trial Hits Enrollment Target; NIH-Funded EAP And MN-001 Diabetes Study Near Completion MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), provides a…